Neurogenomics Market Size, Share, Forecast, & Trends Analysis by Offering (NGS [Kits {Library Prep, QC, DNA Extraction}, Systems], PCR, Microarrays {Protein, DNA, RNA, Tissue}, Software) Application (Research, Clinical) End User - Global Forecast to 2031

Neurogenomics Market Size, Share, Forecast, & Trends Analysis by Offering (NGS [Kits {Library Prep, QC, DNA Extraction}, Systems], PCR, Microarrays {Protein, DNA, RNA, Tissue}, Software) Application (Research, Clinical) End User - Global Forecast to 2031

Neurogenomics Market Size, Share, Forecast, & Trends Analysis by Offering (NGS [Kits {Library Prep, QC, DNA Extraction}, Systems], PCR, Microarrays {Protein, DNA, RNA, Tissue}, Software), Application (Research, Clinical), End User—Global Forecast to 2031

The neurogenomics market is projected to reach $4.68 billion by 2031 at a CAGR of 16.6% from 2024 to 2031.

Succeeding extensive secondary and primary research and an in-depth analysis of the market scenario, the report provides an analysis of key industry drivers, restraints, opportunities, and challenges.

The growth of the neurogenomics market is driven by the declining costs of sequencing, the increasing prevalence of neurological disorders, the growing utilization of advanced sequencing technologies in disease diagnostics & precision medicine, increasing pharmaceutical R&D expenditures, improvements in regulatory & reimbursement scenarios for gene sequencing, rising healthcare expenditures, increasing funding for research activities, the growing need for the early detection & prevention of neurological disorders, technological advancements in neurogenomics products, and government initiatives promoting the use of sequencing in clinical & research applications. However, the high prices of neurogenomics products, the low chances of identifying positive, actionable mutations for precision medicine, and ethical & legal issues related to sequencing-based diagnosis are factors restraining the growth of this market.

Furthermore, the increasing adoption of targeted therapies, emerging economies, and rising awareness regarding neurological disorders are expected to generate growth opportunities for market stakeholders. However, the dynamic regulatory landscape, the limited expertise & sequencing capabilities of small & medium-sized laboratories, the shortage of sequencing professionals, and the high capital investments required for sequencing setups are major challenges impacting the growth of the neurogenomics market.

The report includes a competitive landscape based on an extensive assessment of the product portfolios, geographic presence, and key strategic developments of leading market players during the four years (2021–2024). The key players operating in the neurogenomics market are Illumina, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), QIAGEN N.V. (Netherlands), Agilent Technologies, Inc. (U.S.), Revvity, Inc. (U.S.), Pacific Biosciences of California Inc. (U.S.), Danaher Corporation (U.S.), Oxford Nanopore Technologies Plc. (U.K.), and MGI Tech Co., Ltd. (China).

Among the offerings studied in this report, in 2024, the Next-generation Sequencing (NGS) segment is expected to account for the largest share of 63.9% of the neurogenomics market. The large share of this segment is attributed to the rising demand for next-generation sequencing solutions from end users, the recurring use of sample preparation consumables in neurological research, the increasing affordability of NGS, and the growth in genomic studies.

Among the applications studied in this report, in 2024, the research segment is expected to account for the larger share of 61.6% of the neurogenomics market. The large share of this segment is attributed to the decreasing costs of advanced solutions used in neurogenomics, increasing R&D efforts of pharmaceutical and biotechnology companies for advancing precision medicine & drug discovery, and the use of informatics solutions to find pharmacological targets, confirm therapeutic hypotheses, and predict the potential safety of inhibitory compounds aimed at molecular targets.

Among the end users studied in this report, in 2024, the pharmaceutical & biotechnology companies segment is expected to account for the largest share of 44.6% of the neurogenomics market. The large market share of this segment is attributed to pharmaceutical & biotechnology companies’ increasing R&D spending and the rising incidence of neurological diseases, which drives the adoption of advanced products among pharmaceutical & biotechnology companies.

Scope of the Report:

Neurogenomics Market Assessment—by Offering

Next-generation Sequencing
Systems
Kits & Reagents
DNA Extraction & Amplification Kits & Reagents
Library Preparation & Target Enrichment Kits & Reagents
Quality Control Kits & Reagents
Other Kits & Reagents
Polymerase Chain Reaction (PCR)
Systems
Kits & Reagents
Microarray
Readers & Scanners
Kits & Reagents
DNA & RNA Microarray Kits & Reagents
Protein Microarray Kits & Reagents
Tissue Microarray Kits & Reagents
Software & Services

Neurogenomics Market Assessment—by Application

Research Applications
Target Identification
Functional Studies
Variant Discovery
Transcription Factor Binding Analysis
Clinical Applications

Neurogenomics Market Assessment—by End User

Pharmaceutical & Biotechnology Companies
Academic & Research Institutes
Hospitals & Diagnostic Laboratories

Neurogenomics Market Assessment—by Geography

North America
U.S.
Canada
Europe
Germany
France
Italy
U.K.
Spain
Rest of Europe (RoE)
Asia-Pacific
China
Japan
India
Rest of Asia-Pacific (RoAPAC)
Latin America
Middle East & Africa

Global Neurogenomics Market - Report Summary

Report Metrics	Details
Years Considered	2016 - 2021
Base Year	2023
Forecast Period	2024-2031
Page Count	250
Units Referenced	Value (USD Million)
Segments/Key Topics	Market by Offering, Application, End User
Regions Covered	North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa
Key Companies Mentioned	Illumina, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), QIAGEN N.V. (Netherlands), Agilent Technologies, Inc. (U.S.), Revvity, Inc. (U.S.), Pacific Biosciences of California Inc. (U.S.), Danaher Corporation (U.S.), Oxford Nanopore Technologies Plc. (U.K.), and MGI Tech Co., Ltd. (China)

FAQs About the Report

What is the focus of the neurogenomics market study?

The global neurogenomics market study focuses on market assessment and opportunity analysis based on the sales of neurogenomics products across various market segments. The report also includes a competitive analysis based on the leading market players’ product portfolios and key growth strategies adopted in the last three to four years. The report also provides insights on factors impacting market growth, regulatory analysis, pricing analysis, and Porter’s five forces analysis.

What is the size of the neurogenomics market, and at what CAGR is this market projected to grow during 2024–2031?

The global neurogenomics market is projected to reach $4.68 billion by 2031, at a CAGR of 16.6% during the forecast period.

Which offering segment is expected to hold the major share of the market in 2024?

In 2024, the next-generation sequencing (NGS) segment is expected to hold the major share of the global neurogenomics market.

Which is the high-growth application segment of the global neurogenomics market?

The research applications segment is expected to witness the fastest growth during the forecast period 2024–2031.

What are the key factors supporting the growth of this market? What are the major opportunities for existing market players and new entrants in the global neurogenomics market?

The growth of the neurogenomics market is driven by the declining costs of sequencing, the increasing prevalence of neurological disorders, the growing utilization of advanced sequencing technologies in disease diagnostics & precision medicine, increasing pharmaceutical R&D expenditures, improvements in regulatory & reimbursement scenarios for gene sequencing, rising healthcare expenditures, increasing funding for research activities, the growing need for the early detection & prevention of neurological disorders, technological advancements in neurogenomics products, and government initiatives promoting the use of sequencing in clinical & research applications.

Furthermore, the increasing adoption of targeted therapies, emerging economies, and rising awareness regarding neurological disorders are expected to generate growth opportunities for market stakeholders.

Who are the major players operating in the neurogenomics market?

The key players operating in the neurogenomics market are Illumina, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), QIAGEN N.V. (Netherlands), Agilent Technologies, Inc. (U.S.), Revvity, Inc. (U.S.), Pacific Biosciences of California Inc. (U.S.), Danaher Corporation (U.S.), Oxford Nanopore Technologies Plc. (U.K.), and MGI Tech Co., Ltd. (China).

Which regions/countries are likely to offer significant growth opportunities for the vendors in this market during the analysis period?

The countries like China and India are projected to offer significant growth opportunities for the vendors in this market. The growth of this regional market is attributed to the accelerated economic growth in many countries within the region, leading to increased government focus on improving the healthcare sector. This has resulted in high investments to enhance the accessibility of healthcare services, improve healthcare infrastructure, and support drug discovery and genome mapping programs.